DomusVi entered into exclusive negotiations to acquire 100% of the capital of Residalya, in a move designed to significantly densify its territorial coverage within France. The transaction allowed DomusVi to absorb 35 additional facilities and roughly 2,630 beds, bringing its total capacity to over 17,000 beds and narrowing the gap with its primary market competitors. This strategic build-up was motivated by the need to reach a critical industrial scale, merging Residalya’s localized expertise and specialized assets—including the ownership of twelve of its residences—into DomusVi’s global operational platform.

RESIDALYA, which reported an EBITDA margin of LOGIN in 2016, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (13.3x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.